US Edition
Published • loading... • Updated
PulseSight: New Peer-Reviewed Data Highlighting Transferrin’s Therapeutic Potential for Dry AMD
Summary by Eyewire+
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
PulseSight: New Peer-Reviewed Data Highlighting Transferrin’s Therapeutic Potential for Dry AMD
PulseSight Therapeutics welcomed the publication of new scientific data reinforcing the therapeutic promise of transferrin (Tf) for the treatment of dry age-related macular degeneration (AMD). The study, conducted by scientists from Inserm and Cochin Hospital in Paris in collaboration with PulseSight’s researchers, was published this week in Nature Publishing’s Cell Death & Disease[1]. The findings provide evidence that iron dysregulation is not…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
